The assignee ranking for this dataset covers 100 companies across 585 records, with the leading assignee holding 69 records and the top 5 combined holding 282, or 48.2% of all records in scope. This is a concentrated field: the top 10 assignees together hold 69.6% of the 585 records, leaving a long tail of single- or few-filing entrants among the remaining ranked companies. Most of the leading names are large pharmaceutical formulators rather than granulation-equipment manufacturers, which reflects how the search terms anchor on drug-formulation process control.

Filings peaked in 2017 at 47 and declined to 6 by 2024, an 84% drop over the 2021-to-2024 span alone. That said, publication typically lags actual filing by around 18 months, so the 2025 and 2026 figures in any dataset pulled now will understate real activity and should not be treated as confirmation of a continuing decline. Anyone relying on this trend for a go/no-go decision should treat the most recent two years as provisional and re-check after the lag clears.

EP2526931B1, assigned to Deva Holding, claims wet granulation methods using isopropyl alcohol, dichloromethane, methanol, acetone or mixtures of these solvents specifically for manufacturing cetyl myristate, cetyl palmitate, or a combination of the two. The claim scope is narrow: it is tied to a particular solvent-based wet granulation route and to two named excipient compounds, not to wet granulation or endpoint control generally. A formulator using wet granulation for a different active or excipient, or using a different solvent system for these same compounds, is unlikely to fall inside this claim as described.